NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HELIUM, USP (helium) by Advanced Solutions Life Sciences. Approved for asthma, obesity, metabolic syndrome and 1 more indications. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhaled gas product approved in 2013 for asthma, obesity, metabolic syndrome, and aortic valve stenosis. The product operates via inhalation as a gaseous dosage form with no defined pharmacologic mechanism of action or drug class. It represents a unique therapeutic modality in a market dominated by traditional small molecules and biologics.
Peak
Product is at peak lifecycle stage with 4 linked jobs primarily in manufacturing, engineering, and quality assurance roles, indicating operational focus rather than commercial expansion.
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.